← Leaderboards
Martin H Markowitz
Rockefeller University
$24,126,494
Attributed
$25,170,790
Total exposure
29
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–16$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$25,170,790 · 29
By mechanism
R01$14,403,661 · 3
U01$8,076,187 · 1
M01$2,495,278 · 24
P30$195,664 · 1
Top collaborators
- Cecilia C Cheng-Mayer2 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Sanford M Simon$20,890,479
- Irene E Zohn$6,998,533
- Robert B Darnell$69,746,734
- Alexander Shekhtman$4,263,993
- Charles M. Rice$80,497,748
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsHuman Therapy EvaluationAids TherapyAntiaids AgentHuman Immunodeficiency Virus 1Combination ChemotherapyDrug Screening /EvaluationProtease InhibitorAntiviral AgentsLamivudineZidovudineReverse Transcriptase InhibitorsVirus LoadVirus ReplicationResearch PersonnelPharmaceutical PreparationsHiv-1Polymerase Chain ReactionIn VitroInfectionAntiretroviral TherapyClinical Trials
Grant awards (84)
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$920,449
R01 · FY2016 · DA · contact PI
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$916,984
R01 · FY2015 · DA · contact PI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$817,211
R01 · FY2015 · AI · contact PI
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$944,831
R01 · FY2014 · DA · contact PI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$821,392
R01 · FY2014 · AI · contact PI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$1,591,251
R01 · FY2013 · AI · contact PI
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$921,636
R01 · FY2013 · DA · contact PI
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$1,011,463
R01 · FY2012 · DA · contact PI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$497,342
R01 · FY2012 · AI · contact PI
The Transmission and Fitness of Drug Resistant HIV-1$617,570
R01 · FY2011 · AI · contact PI
The Transmission and Fitness of Drug Resistant HIV-1$623,809
R01 · FY2010 · AI · contact PI
The Transmission and Fitness of Drug Resistant HIV-1$612,545
R01 · FY2009 · AI · contact PI
The Transmission and Fitness of Drug Resistant HIV-1$555,738
R01 · FY2009 · AI · contact PI
The Transmission and Fitness of Drug Resistant HIV-1$596,433
R01 · FY2008 · AI · contact PI
The Transmission and Fitness of Drug Resistant HIV-1$604,647
R01 · FY2007 · AI · contact PI
Understanding and Altering the Virologic Setpoint$1,710,399
U01 · FY2006 · AI · contact PI
Understanding and Altering the Virologic Setpoint$1,710,399
U01 · FY2005 · AI
AN OBSERVATIONAL STUDY OF TREATED AND UNTREATED ACUTE AND EARLY HIV-1 INFECTION$988,655
M01 · FY2005 · RR
VIRAL AND HOST FACTORS IN THE TRANSMISSION AND PATHOGENESIS OF HIV$95,859
M01 · FY2005 · RR
SAFETY AND ANTIVIRAL ACTIVITY OF 3 MONOCLONAL ANTIBODIES IN HIV$52,805
M01 · FY2005 · RR
SAFETY, IMMUNOLOGIC &VIROLOGIC EFFECTS OF CYCLOSPORINE A$8,937
M01 · FY2005 · RR
TRANSMISSION &VIRAL DYNAMICS OF DRUG RESISTANT HIV-1$1,621
M01 · FY2005 · RR
ACUTE HIV INFECTION &EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$812
M01 · FY2005 · RR
Understanding and Altering the Virologic Setpoint$1,645,592
U01 · FY2004 · AI
An Observational Study of Treated and Untreated Acute and Early HIV-1 Infection$1,038,670
M01 · FY2004 · RR
TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1$530,668
R01 · FY2004 · AI
HIV-1 viral suppression with ABT-378, Lamivudine, Efavirenz and Tenofovir$101,444
M01 · FY2004 · RR
Viral and Host Factors in the Transmission and Pathogenesis of HIV$75,409
M01 · FY2004 · RR
Once-a-Day Antiviral Regimen to Treat HIV Infection$73,613
M01 · FY2004 · RR
Safety, Tolerance &Antiviral Pharmacodynamics- SCH351125$45,784
M01 · FY2004 · RR
Monitoring of HIV-1 Infected Subjects After Withdrawal of Antiretroviral Therapy$6,283
M01 · FY2004 · RR
Transmission &Viral Dynamics of Drug Resistant HIV-1$3,590
M01 · FY2004 · RR
ACUTE HIV INFECTION &EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$1,796
M01 · FY2004 · RR
Understanding and Altering the Virologic Setpoint$1,582,060
U01 · FY2003 · AI
TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1$515,812
R01 · FY2003 · AI
Understanding and Altering the Virologic Setpoint$1,427,737
U01 · FY2002 · AI
TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1$421,356
R01 · FY2002 · AI
ANTIRETROVIRAL THERAPY W/ EPIVIR, ABACAVIR &RENAVIR IN COMBINATION$0
M01 · FY2002 · RR
COMBINATION THERAPY RITONAVIR (ABT 538), LAMIVUDINE AND ZIDOVUDINE IN HIV$0
M01 · FY2002 · RR
MK-0639 (INDINAVIR SULFATE) + AZT + 3TC FOR ACUTE HIV1 INFECTION$0
M01 · FY2002 · RR
PHASE II PILOT STUDY OF VIRACEPT, ZIDOVUDINE &LAMIVUDINE$0
M01 · FY2002 · RR
SAFETY &EFFICACY OF RITONAVIR IN COMBINATION WITH SAQUINAVIR IN HIV INFECTION$0
M01 · FY2002 · RR
PHASE II STUDY OF FOUR DRUG COMBINATION REGIMEN INCLUDING SAQUINAVIR$0
M01 · FY2002 · RR
LYMPHATIC TISSUE SAMPLING TO QUANTITATE TISSUE ASSOCIATED HIV 1$0
M01 · FY2002 · RR
OPEN LABEL TRIAL--EVALUATE EFFICACY &SAFETY OF QUADRUPLE ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
OPEN LABEL SINGLE CENTER TRIAL--EVALUATE EFFICACY &SAFETY OF ANTIVIRAL THERAPY$0
M01 · FY2002 · RR
EFFECT ON VIRAL LOAD OF DELAYED PHENOTYPING VS IMMEDIATE PHENOTYPING$0
M01 · FY2002 · RR
INTRAVENOUS OKT3 INFUSIONS TO ACTIVATE RESTING MEMORY CD4 POSITIVE CELLS$0
M01 · FY2002 · RR
MKC 442--TRIPLE DRUG COMBINATION IN PATIENTS W/ HIV$0
M01 · FY2002 · RR
MONITORING OF HIV 1 INFECTED SUBJECTS AFTER WITHDRAWAL OF ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
ANTIRETROVIRAL REGIMENS WITH ABACAVIR AND EFAVIRENZ$0
M01 · FY2002 · RR
CORE--CLINICAL$0
P30 · FY2002 · AI
TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1$516,945
R01 · FY2001 · AI
CORE--CLINICAL$0
P30 · FY2001 · AI
ANTIRETROVIRAL REGIMENS WITH ABACAVIR AND EFAVIRENZ$0
M01 · FY2001 · RR
MONITORING OF HIV 1 INFECTED SUBJECTS AFTER WITHDRAWAL OF ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
MKC 442--TRIPLE DRUG COMBINATION IN PATIENTS W/ HIV$0
M01 · FY2001 · RR
ANTIRETROVIRAL THERAPY W/ EPIVIR, ABACAVIR &RENAVIR IN COMBINATION$0
M01 · FY2001 · RR
INTRAVENOUS OKT3 INFUSIONS TO ACTIVATE RESTING MEMORY CD4 POSITIVE CELLS$0
M01 · FY2001 · RR
EFFECT ON VIRAL LOAD OF DELAYED PHENOTYPING VS IMMEDIATE PHENOTYPING$0
M01 · FY2001 · RR
OPEN LABEL SINGLE CENTER TRIAL--EVALUATE EFFICACY &SAFETY OF ANTIVIRAL THERAPY$0
M01 · FY2001 · RR
OPEN LABEL TRIAL--EVALUATE EFFICACY &SAFETY OF QUADRUPLE ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
LYMPHATIC TISSUE SAMPLING TO QUANTITATE TISSUE ASSOCIATED HIV 1$0
M01 · FY2001 · RR
PHASE II STUDY OF FOUR DRUG COMBINATION REGIMEN INCLUDING SAQUINAVIR$0
M01 · FY2001 · RR
SAFETY &EFFICACY OF RITONAVIR IN COMBINATION WITH SAQUINAVIR IN HIV INFECTION$0
M01 · FY2001 · RR
PHASE II PILOT STUDY OF VIRACEPT, ZIDOVUDINE &LAMIVUDINE$0
M01 · FY2001 · RR
COMBINATION THERAPY RITONAVIR (ABT 538), LAMIVUDINE AND ZIDOVUDINE IN HIV$0
M01 · FY2001 · RR
MK-0639 (INDINAVIR SULFATE) + AZT + 3TC FOR ACUTE HIV1 INFECTION$0
M01 · FY2001 · RR
TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1$365,579
R01 · FY2000 · AI
CORE--CLINICAL$195,664
P30 · FY2000 · AI
MK-0639 (INDINAVIR SULFATE) + AZT + 3TC FOR ACUTE HIV1 INFECTION$0
M01 · FY2000 · RR
ANTIRETROVIRAL REGIMENS WITH ABACAVIR AND EFAVIRENZ$0
M01 · FY2000 · RR
MONITORING OF HIV 1 INFECTED SUBJECTS AFTER WITHDRAWAL OF ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
MKC 442--TRIPLE DRUG COMBINATION IN PATIENTS W/ HIV$0
M01 · FY2000 · RR
ANTIRETROVIRAL THERAPY W/ EPIVIR, ABACAVIR &RENAVIR IN COMBINATION$0
M01 · FY2000 · RR
INTRAVENOUS OKT3 INFUSIONS TO ACTIVATE RESTING MEMORY CD4 POSITIVE CELLS$0
M01 · FY2000 · RR
EFFECT ON VIRAL LOAD OF DELAYED PHENOTYPING VS IMMEDIATE PHENOTYPING$0
M01 · FY2000 · RR
OPEN LABEL SINGLE CENTER TRIAL--EVALUATE EFFICACY &SAFETY OF ANTIVIRAL THERAPY$0
M01 · FY2000 · RR
OPEN LABEL TRIAL--EVALUATE EFFICACY &SAFETY OF QUADRUPLE ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
LYMPHATIC TISSUE SAMPLING TO QUANTITATE TISSUE ASSOCIATED HIV 1$0
M01 · FY2000 · RR
PHASE II STUDY OF FOUR DRUG COMBINATION REGIMEN INCLUDING SAQUINAVIR$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF RITONAVIR IN COMBINATION WITH SAQUINAVIR IN HIV INFECTION$0
M01 · FY2000 · RR
PHASE II PILOT STUDY OF VIRACEPT, ZIDOVUDINE &LAMIVUDINE$0
M01 · FY2000 · RR
COMBINATION THERAPY RITONAVIR (ABT 538), LAMIVUDINE AND ZIDOVUDINE IN HIV$0
M01 · FY2000 · RR